- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Harbin Pharmaceutical Group Co Ltd (600664)
Harbin Pharmaceutical Group Co Ltd stock price live, this page displays SS 600664 stock exchange data. View the 600664 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Harbin Pharmaceutical Group Co Ltd real time stock price chart below.
What Is the Harbin Pharmaceutical Group Co Ltd Stock Price Today?
The Harbin Pharmaceutical Group Co Ltd stock price today is 3.07.
What Is the Stock Symbol for Harbin Pharmaceutical Group Co Ltd?
The stock symbol for Harbin Pharmaceutical Group Co Ltd is "600664."
What Stock Exchange Does Harbin Pharmaceutical Group Co Ltd Trade On?
Harbin Pharmaceutical Group Co Ltd is listed and trades on the Shanghai stock exchange.
Is Harbin Pharmaceutical Group Co Ltd a Good Stock to Buy?
Determining whether Harbin Pharmaceutical Group Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 600664 quote. (ISIN: CNE0000009T3)
What Is the Harbin Pharmaceutical Group Co Ltd Stock Price Today?
The Harbin Pharmaceutical Group Co Ltd stock price today is 3.07.
What Is the Stock Symbol for Harbin Pharmaceutical Group Co Ltd?
The stock symbol for Harbin Pharmaceutical Group Co Ltd is "600664."
What Stock Exchange Does Harbin Pharmaceutical Group Co Ltd Trade On?
Harbin Pharmaceutical Group Co Ltd is listed and trades on the Shanghai stock exchange.
Is Harbin Pharmaceutical Group Co Ltd a Good Stock to Buy?
Determining whether Harbin Pharmaceutical Group Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 600664 quote. (ISIN: CNE0000009T3)
Shanghai
Currency in CNY
3.07
-0.11(-3.46%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.05
3.17
52 wk Range
2.84
4.88
600664 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.053.17
52 wk Range
2.844.88
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
600664 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
4.31
Upside
+40.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.31
(+40.39% Upside)
Earnings
Latest Release
Apr 24, 2026
EPS / Forecast
0,06 / --
Revenue / Forecast
4,18B / --
Compare 600664 to Peers and Sector
Metrics to compare | 600664 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600664PeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.0x | 16.4x | −0.4x | |
PEG Ratio | −0.46 | 0.25 | 0.00 | |
Price/Book | 1.3x | 1.7x | 2.6x | |
Price / LTM Sales | 0.5x | 2.1x | 3.1x | |
Upside (Analyst Target) | 40.4% | 35.5% | 48.3% | |
Fair Value Upside | Unlock | 19.2% | 6.1% | Unlock |
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron and vitamin B12 oral solutions, calcium, iron, and zinc oral solutions, ceftriaxone sodium injections, Qufenggutong gel ointment, GNC Vitapak nutritional pack, lacidipine tablets, GNC fish oil capsules, coenzyme Q10 and panthenol soft capsules, GNC children's liquid calcium magnesium zinc, penicillin sodium, acetaminophen and chlorpheniramine maleate granules, glucosamine chondroitin calcium tablets, ceftriaxone sodium for injection, GNC milk thistle extract tablets and capsules, and compound sulfamethoxazole oral tablets. The company is also involved in culture, science and technology, pharmaceutical commercial and industry, property, and investment activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Harbin Pharm (600664) Stock Price Today?
The Harbin Pharm stock price today is 3,07 CNY.
What Stock Exchange Does Harbin Pharm Trade On?
Harbin Pharm is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for Harbin Pharm?
The stock symbol for Harbin Pharm is "600664."
What Is the Harbin Pharm Market Cap?
As of today, Harbin Pharm market cap is 7,73B CNY.
What Is Harbin Pharm's Earnings Per Share (TTM)?
The Harbin Pharm EPS (TTM) is 0,12.
When Is the Next Harbin Pharm Earnings Date?
Harbin Pharm will release its next earnings report on Aug 26, 2026.
From a Technical Analysis Perspective, Is 600664 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Harbin Pharm Stock Split?
Harbin Pharm has split 6 times.
How Many Employees Does Harbin Pharm Have?
Harbin Pharm has 10039 employees.
What is the current trading status of Harbin Pharm (600664)?
As of Jul 07, 2026, Harbin Pharm (600664) is trading at a price of 3,07 CNY, with a previous close of 3,18 CNY. The stock has fluctuated within a day range of 3,05 CNY to 3,17 CNY, while its 52-week range spans from 2,84 CNY to 4,88 CNY.
What Is Harbin Pharm (600664) Price Target According to Analysts?
The average 12-month price target for Harbin Pharm is 4,31 CNY, with a high estimate of 4.31 CNY and a low estimate of 4.31 CNY. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +40,39% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.